BCL family-mediated resistance to JAK2 inhibitors
Methods and compositions for diagnosing and treating JAK2 inhibitor resistant cancers are disclosed. In the disclosed methods, AKT and/or PBK inhibitors, ERK/MEK inhibitors, BCL-XL protein inhibitors, or combinations thereof are administered to a subject to reverse JAK2 inhibitor resistance. Accordingly, compositions containing such inhibitors may be used along with JAK2 inhibitors to successfully treat JAK2 inhibitor resistant cancers.
Interested in this Technology?
Submit your interest below.